資源描述：
《復(fù)方牛胎肝提取物治療乙型肝炎肝硬化療效觀察.doc》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、復(fù)方牛胎肝提取物治療乙型肝炎肝硬化療效觀察盧敏，毛華，黃純熾，唐銀麗，張能友，席建東【摘要】H的探討復(fù)方牛胎肝提取物治療乙型肝炎肝硬化患者的療效。方法將120例乙型肝炎肝硬化患者隨機(jī)分為治療組80例和對(duì)照組40例。給予治療組復(fù)方牛胎肝聯(lián)合基礎(chǔ)護(hù)肝治療，對(duì)照組僅予以基礎(chǔ)護(hù)肝治療，療程3個(gè)刀，對(duì)比兩組患者治療前后肝功能、肝臟硬度值(LSM),以及B超檢測(cè)門(mén)靜脈內(nèi)徑、脾臟厚度、脾靜脈寬度的變化。結(jié)果在3個(gè)月治療結(jié)朿吋，治療組患者血清TBIL為(33.0±2.07)屮nol/L、ALT為(36.40±5.86)U/L、
2、LSM為(10.78±1」5)Kpa,均較對(duì)照組顯著下降[分別為(48.62±4.24)pmol/L、(52.60±7.3)U/L、(15.26±2.17)Kpa,P<0.05];治療組血清ALB水平為(35.0±1.58)g/L,較對(duì)照組明顯升高[(31±1.58)g/L,P<0.05];治療組門(mén)靜脈內(nèi)徑為(1.26±0.08)cm,脾臟厚度為(3?97±0.04)cm,脾靜脈寬度為(0.87±0.02)cm,均較對(duì)照組顯著降低[分別為(1.36±0.05)cm、(4.20±0.10)cm>(0.92±0.0
3、2)cm,P<0.05]o結(jié)論復(fù)方牛胎肝提取物可顯著改善乙型肝炎肝硬化患者的肝功能，減輕肝纖維化程度。【關(guān)鍵詞】肝硬化;乙型肝炎;復(fù)方牛胎肝提取物;療效DOI：10.3969/j.issn.1672-5069.2015.02.011EfficacyofcompoundembryonicbovineliverextractinpatientswithhepatitisBrelatedlivercirrhosisLuMin,MaoHua,HuangChunchi,etal.DepartmentofGastroent
4、erology,ZhujiangHospitalAffiliatedtoSouthernMedicalUniversity,Guangzhou510282,GuangdongProvince,China[Abstract]ObjectiveToinvestigatetheeffectofcompoundembryonicbovineliverextractinpatientswithhepatitisBrelatedlivercirrhosis.MethodsOnehundredandtwentypatient
5、swithhepatitisBinducedlivercirrhosiswererandomlydividedintotwogroups,with80intreatmentgroupreceivingcompoundembryonicbovineliverextracttabletsatthebaseofbasicliver-protectingtreatmentand40incontrolgroupreceivingthebasicliv?er-protectingtreatmentonlyfor3month
6、s.Liverfunctiontests,liverstiffnessmeasurement(LSM)byFibrotouch,andportalveindiameters,spleenthicknessandsplenicveinwidthbeforeandaftertreatmentwerecomparedinbothgroups?ResultsAttheendof3-monthtreatment,scrumTBIL,ALT,andLSMvaluesinpatientsintreatmentgroupwer
7、e(33.0±2.07)pmol/L,(36.40±5.86)U/L，(10.78±1.15)Kpa,respectively,significantlydecreasedascomparedwiththoseinthecontrols[(48.62±4.24)pmol/L,(52.60±7.3)U/L,(15?26±2」7)Kpa,respectively,P<0.05forall];scrumALBlevelsinpatientsintreatmentgroupincreasedsignificantlyc
8、omparedwiththatincontrols[(35.0±1.58)g/Lvs.(31±1.58)g/L,P<0.05];portalveindiameters,spleenthicknessandsplenicveinwidthsremarkablydecreasedcomparedwiththoseinpatientsinthecontrolgroup[(1.26±0.08)
